07.17.08 Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial with MPI-676 in Endometriosis02.06.08
Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement with AstraZeneca
09.19.07
Meditrina Pharmaceuticals, Inc. Announces Exclusive Global Manufacturing Agreement with Pfizer Centresource (PCS) for Femathina™ (MPI-674)
![]()
Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women’s reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs.
By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina’s novel therapies have the potential to significantly alter the way these women’s health conditions are treated.